Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine and lithium monotherapy in adult patients with bipolar depression
2004-004681-33Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine and lithium carbonate in bipolar disorder (BD) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change from randomisation to Week 8 in MADRS total score. Started Mar 2005; status: completed.
02
Drugs
quetiapinelithium carbonate
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2004-004681-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004681-33.